Table 1.

Clinicopathological characteristics of patients with PDAC stratified by tumor site.

Characteristics		Tumor site				Characteristics		Tumor site
		Head	Body/tail	N	P			Head	Body/tail	N	P
Whole cohort		247	55	302		Macrovascular invasion	Absence	231	42	273	<0.001
Age	≤60 years	140	24	164	0.099		Presence	16	13	29
	>60 years	107	31	138		Microvascular invasion	Absence	162	44	206	0.039
Gender	Male	97	22	119	1.000		Presence	85	11	96
	Female	150	33	183		Lymph vessel invasion	Absence	125	15	140	0.031
Recurrence	Absence	148	26	174	0.098		Presence	122	40	162
	Presence	99	29	128		Perineural invasion	Absence	127	19	146	0.026
Time to recurrence	Absence	111	18	129	0.211		Presence	120	36	156
	2–6 M	54	18	72		Adjacent organ invasion	Absence	247	23	270	<0.001
	6–12 M	46	11	57			Presence	0	32	32
	12–24 M	23	3	26		LNR	0	135	38	173	0.140
	>24 M	13	5	18			0–0.16	58	8	66
Recurrence patterns	Absence	148	26	174	0.157		>0.16	54	9	63
	Local	32	7	39		Satellite foci	Absence	243	44	287	<0.001
	Liver-only	39	10	49			Presence	4	11	15
	Lung-only	8	4	12		TNM stage	IA	49	5	54	<0.001
	Other sites	2	3	5			IB	64	10	74
	Local + distant	11	3	14			IIA	22	13	35
	Multiple	7	2	9			IIB	71	8	79
LN metastasis	Absence	136	38	174	0.070		III	41	19	60
	Presence	111	17	128		Imaging tumor size (cm)	≤2	97	7	104	<0.001
LN5 metastasis	Absence	245	55	300	1.000		2–4	123	18	141
	Presence	2	0	2			>4	27	30	57
LN6 metastasis	Absence	243	55	298	1.000	Imaging LN metastasis	Absence	133	42	175	0.002
	Presence	4	0	4			Presence	114	13	127
LN7 metastasis	Absence	242	54	296	1.000	Imaging vascular invasion	Absence	209	25	234	<0.001
	Presence	5	1	6			Presence	38	30	68
LN8 metastasis	Absence	241	53	294	0.641	Imaging LN size (cm)	≤0.5	139	38	177	0.216
	Presence	6	2	8			0.5–1	55	9	64
LN9 metastasis	Absence	239	53	292	1.000		>1	53	8	61
	Presence	8	2	10		PI	0	154	45	199	0.022
LN10 metastasis	Absence	247	48	295	<0.001		1	76	8	84
	Presence	0	7	7			2	17	2	19
LN11 metastasis	Absence	247	47	294	<0.001	NLR	≤3.32	153	44	197	0.012
	Presence	0	8	8			>3.32	94	11	105
LN12 metastasis	Absence	213	55	268	0.001	dNLR	≤3.32	79	21	100	0.429
	Presence	34	0	34			>3.32	168	34	202
LN13 metastasis	Absence	178	53	231	0.001	PLR	≤98.13	21	15	36	<0.001
	Presence	69	2	71			>98.13	226	40	266
LN14 metastasis	Absence	227	54	281	0.141	PNI	0	54	11	65	0.857
	Presence	20	1	21			1	193	44	37
LN15 metastasis	Absence	241	53	294	0.641	SII	≤1000	158	48	206	0.001
	Presence	6	2	8			>1000	89	7	96
LN16 metastasis	Absence	231	53	284	0.544	mGPS	0	157	45	202	0.033
	Presence	16	2	18			1	60	7	67
LN17 metastasis	Absence	238	55	293	0.373		2	30	3	33
	Presence	9	0	9		WBC	≤10	227	53	280	0.389
LN18 metastasis	Absence	244	52	296	0.076		>10	20	2	22
	Presence	3	3	6		ALB (g/L)	≤35	43	3	46	0.023
Positive LN number	0	135	38	173	0.142		>35	204	52	256
	1–3	83	12	95		CRP (ng/L)	≤3	157	45	202	0.011
	>4	29	5	34			>3	90	10	100
Pancreatic membrane invasion	Absence	163	20	183	<0.001	CA19-9 (U/ml)	≤35	49	10	59	0.853
	Presence	84	35	119			>35	198	45	243
Tumor size (cm)	≤2	82	6	88	<0.001	CEA (ng/ml)	≤5	172	33	205	0.201
	2–4	125	21	146			>5	75	22	97
	>4	40	28	68		HBV infection	Absence	229	54	283	0.216
Tumor differentiation	Well	0	2	2	0.010		Presence	18	1	19
	Moderate	125	28	153		Chemotherapy	No	134	26	160	0.373
	Poor	122	25	147			Yes	113	29	142
Hemorrhage	Absence	241	54	295	0.626	Biliary fistula	Absence	212	47	259	0.543
	Presence	6	1	7			Presence	35	8	43
Pancreatic fistula	Absence	193	48	241	0.141	Abdominal infection	Absence	225	54	279	0.091
	Presence	54	7	61			Presence	22	1	23

M, month; LN, lymph node metastasis; LNR, lymph node ratio; TNM, tumor-node-metastasis stage; PI, prognostic index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell count; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus.